Valneva Enrolls Teens in COVID-19 Vaccine Late-Stage Trial

September 24, 2021

Valneva has begun recruiting teenagers in a phase 3 study of its inactivated COVID-19 vaccine candidate, VLA2001, in the United Kingdom.

An estimated 660 adolescents, ages 12 to 17, are expected to participate in the UK trial, and the company plans to eventually enroll children younger than 12 years old, pending results from the older participants.

Topline data from a separate, ongoing late-stage trial in adults should be available early in the fourth quarter, the company said.

View today's stories